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Trained immunity (TI) is a de facto innate immune memory program induced in monocytes/macrophages
by exposure to pathogens or vaccines, which evolved as protection against infections. TI is characterized
by immunometabolic changes and histone post-translational modifications, which enhance production of
pro-inflammatory cytokines. As aberrant activation of TI is implicated in inflammatory diseases, tight regu-
lation is critical; however, the mechanisms responsible for this modulation remain elusive. Interleukin-37
(IL-37) is an anti-inflammatory cytokine that curbs inflammation and modulates metabolic pathways. In
this study, we show that administration of recombinant IL-37 abrogates the protective effects of TI in vivo,
as revealed by reduced host pro-inflammatory responses and survival to disseminated candidiasis.
Mechanistically, IL-37 reverses the immunometabolic changes and histone post-translational modifica-
tions characteristic of TI in monocytes, thus suppressing cytokine production in response to infection.
IL-37 thereby emerges as an inhibitor of TI and as a potential therapeutic target in immune-mediated
pathologies.
INTRODUCTION
Immunological memory is traditionally considered a prerogative
of the adaptive immune system. Conversely, the innate immune
system is classically viewed as non-specific and unable to build
memory. However, activated innate immune cells undergo
long-term functional reprogramming, resulting in the ability to
mount more robust inflammatory responses upon restimula-
tion. Specifically, after monocytes or macrophages are
exposed to certain pathogens, microbial components, or vac-
cines, restimulation with non-related pathogens results in
enhanced production of pro-inflammatory cytokines (Netea
et al., 2016, 2020a; Quintin et al., 2012). This induction of
non-specific memory in innate immune cells is termed ‘‘trained
immunity’’ (TI) (Netea et al., 2016), and it is mechanistically
characterized by changes in epigenetic regulation and cell
energy metabolism, sustaining enhanced production of pro-in-
flammatory cytokines (Arts et al., 2016a, 2016b; Cheng et al.,
2014). In particular, a shift from oxidative phosphorylation to
aerobic glycolysis (‘‘Warburg effect’’) is essential for the induc-
tion of TI responses induced by the fungal cell wall component
b-glucan (Cheng et al., 2014).
TI likely evolved in organisms without adaptive immune sys-
tems, as a mechanism to provide protection from repeated in-
fections by inducing a state of pro-inflammatory activation.
However, overly activated TI programs can induce detrimental
inflammation and contribute to the development of inflamma-
tory diseases (Bekkering et al., 2014, 2018; Mulder et al.,
2019; Netea et al., 2016). It is thereby likely that tight regula-
tory mechanisms are in place to prevent inappropriate
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activation of TI. However, although several activating stimuli
have been described, mechanisms suppressing TI remain
largely elusive. A crucial, unanswered question pertains to
the intercellular events and endogenous mediators that regu-
late TI.
Cytokines of the interleukin-1 (IL-1) family play a central role in
innate immune responses in general, as well as TI specifically; for
example, IL-1bproduction is enhanced inTI,while alsohaving the
capacity to induceTIper se (Moorlag et al., 2018).Members of the
IL-1 family exhibiting anti-inflammatory properties are thereby
highly promising candidates among possible regulators of TI.
IL-37 is a unique IL-1 family member that curbs innate inflamma-
tion by suppressing production of cytokines (Cavalli and Dinar-
ello, 2018; Nold et al., 2010) and confers protection against
several models of inflammatory disease (Cavalli et al., 2016; Cav-
alli et al., 2017b; McNamee et al., 2011). In fact, the biologic ef-
fects of IL-37 extend beyond suppression of inflammatory cyto-
kines and include complex effects on cell metabolism, such as
activation of AMPK, suppression of mTOR, and increased oxida-
tive phosphorylation, which represent a reversal of the Warburg
effect (Cavalli et al., 2017a; Nold et al., 2010). Given this dual
efficacy in curbing inflammation and in modulating metabolic
pathways, IL-37 was a potential regulator of TI. In this study,
we investigated the role of IL-37 as an inhibitor of TI.
RESULTS
IL-37 andTI haveopposite effects of onhost defense in a
model of Candida infection
We first evaluated the effects of administration of recombinant
IL-37 on host survival in a model of disseminated Candida
albicans infection. We chose this model because in previous
studies, transgenic mice expressing human IL-37 had increased
susceptibility to C. albicans (van de Veerdonk et al., 2015).
Experimental animals received recombinant IL-37 (0.12 mg/kg
of body weight) prior to a lethal inoculum of C. albicans yeast
(2 3 106 colony-forming units [CFU]/mouse); survival and
changes in body weight were monitored daily for 2 weeks.
Mice receiving IL-37 exhibited a clear reduction in survival (Fig-
ure 1A), which was mirrored by a progressive reduction in
body weight, an additional indicator of health (Figure 1B). In a
separate experiment, animals were sacrificed 4 days after
C. albicans infection, and fungal burden was assessed in the kid-
ney, a target organ for disseminated candidiasis. Mice receiving
IL-37 had a markedly increased kidney fungal burden
(Figure 1C).
Training with fungal cell wall b-glucan is known to induce func-
tional reprogramming of monocytic cells, resulting in TI and pro-
tection from subsequent C. albicans infection (Quintin et al.,
Figure 1. Effects of IL-37 and TI on the host response to C. albicans infection
(A) Survival rate of mice to systemic candidiasis following administration of IL-37.
(B) Weight loss.
(C) Fungal outgrowth in the kidneys.
(D) Survival rate of mice to systemic candidiasis following stimulation with b-glucan.
(E) Weight loss.
(F) Fungal outgrowth in the kidneys.
Animal survival and weight were assessed daily for 2 weeks (two experiments, product limit method of Kaplan and Meier, n = 10 mice per group). Fungal
outgrowth was assessed in the kidneys 4 days after C. albicans infection (Mann-Whitney, n = 5 mice per group). *p < 0.05.




2012). In a separate experiment, mice received a single injection
of b-glucan (1 mg intraperitoneally [i.p.]) or vehicle 3 days prior to
the C. albicans inoculum. Mice treated with b-glucan exhibited
an increase in survival (Figure 1D), which was paralleled by re-
ductions in weight loss (Figure 1E) and fungal burden in the kid-
neys (Figure 1F).
IL-37 abrogates the host defense and survival benefit
conferred by TI
We thereafter investigated whether administration of recombi-
nant IL-37 could revert the beneficial effects on host survival
observed in mice trained with b-glucan. Mice received treatment
with b-glucan and IL-37 prior to inoculum ofC. albicans yeast. As
shown in Figure 2A, upon administration of IL-37 the survival
benefit conferred by TI was abrogated, and animal survival
decreased to near baseline levels. Animals receiving training
with b-glucan prior to infection exhibited lower fungal burden
compared with vehicle-treated animals (Figure 2B); however,
these protective effects were completely abrogated in mice
receiving IL-37 in addition to b-glucan.
The protection against infection afforded by TI depends on
increased production of pro-inflammatory cytokines by mono-
cytes. We thus determined changes in the production of cyto-
kines in the kidneys of experimental animals 4 days afterCandida
infection. Levels of IL-1b, IL-6, and TNF-a (Figures 2C–2E) were
significantly increased in the kidneys of b-glucan-treated ani-
mals, a finding consistent with reduced kidney fungal burden
and increased survival. However, in mice receiving IL-37 in addi-
tion to b-glucan, production of pro-inflammatory mediators re-
turned to baseline levels. Of note, the inhibitory effects of IL-37
on TI were lost in mice lacking the IL-1 family receptor 8 (IL-
1R8), which transduces the anti-inflammatory effects of IL-37
(Nold-Petry et al., 2015). Indeed, monocytes of trained mice
lacking IL-1R8 and receiving IL-37 in vivo retained enhanced
cytokine production upon secondary stimulation with LPS
in vitro (Figures S1A and S1B).
As neutrophils are key players in host protection against
Candida infection (Swamydas et al., 2016), we also determined
changes in the recruitment and activation of neutrophils into
the kidney of experimental animals 4 days after Candida infec-
tion. Levels of the neutrophil chemoattractant KC (Figure 2F),
as well as the activation marker MPO (Figure 2G), were signifi-
cantly increased in kidney homogenates of b-glucan-treated an-
imals, a finding consistent with increased protection in trained
mice. However, in mice also receiving IL-37 in addition to
b-glucan, levels of KC and MPO returned to near baseline levels.
These effects on neutrophil-related mediators were mirrored by
functional differences in neutrophil recruitment: in chemotaxis
assays, kidney homogenates from animals treated with b-glucan
attracted significantly more neutrophils compared with controls
(migration assay, Figure 2H). Again, these effects were abro-
gated inmice receiving IL-37 in addition to b-glucan training. His-
tology studies confirmed these findings (Figure 2I).
IL-37 reverses glycolysis and epigenetic changes
induced by TI
Pro-inflammatory activation of monocytes in TI is sustained by
metabolic reprogramming,asexemplifiedby increasedglycolysis,
accumulation of fumarate and glutamine utilization, and mevalo-
nate accumulation in the cholesterol synthesis pathway (Arts
et al., 2016a; Bekkering et al., 2018). We therefore evaluated
whether abrogation of the protective effects of TI upon treatment
with IL-37 was associated with metabolic changes in monocytes.
Mice received IL-37 and b-glucan in vivo, and bone marrow-
derived monocytes were subjected to metabolic analyses.
Partial-least-squares discriminant analysis (PLS-DA) indicated
that TI with b-glucan and IL-37 has differential effects on the
metabolic landscape of monocytes (Figure 3A), consistent with
previous evidence of differential activation of mTOR and
AMPK, two critical enzymes regulating metabolic reprogram-
ming (Cavalli et al., 2017a; Cheng et al., 2014). Pathway analysis
revealed that the main differentially modulated pathways of
monocytes during TI induced by b-glucan or upon concomitant
treatment with IL-37 included purine metabolism, the gluta-
mine/glutamate pathway, and tryptophan metabolism
(Figure 3B).
As expected, TI was associated with increased glycolysis, as
demonstrated by accumulation of phosphoglycerate, phospho-
enolpyruvate, and lactate; however, treatment with IL-37
restored these metabolites to baseline levels (Figure 3C). Similar
changes were observed in pentose phosphate pathway interme-
diates and taken together, these findings are consistent with an
inhibition of glycolysis (Figure 3C). To confirm these findings,
bone marrow-derived monocytes stimulated with b-glucan or
also treated with IL-37 were evaluated using the Extracellular
Flux Analyzer (Seahorse) to determine changes in the extracel-
lular acidification rate (ECAR), which is a proxy for glycolytic ac-
tivity. Training with b-glucan resulted in increased ECAR,
whereas concomitant treatment with IL-37 reduced glycolysis
and glycolytic capacity (Figures 3D and 3E); training with
b-glucan also increased basal oxygen consumption rate, as pre-
viously reported (Cheng et al., 2014), and this was also reverted
by IL-37 (Figure S2). Furthermore, treatment with IL-37 reduced
expression of genes encoding glycolytic enzymes, hexokinase
(HK1), and phosphofructokinase (PK) (Figure 3F). In TI induced
by b-glucan, increased glycolysis depends on activation of the
AKT/mTOR/HIF-1a signaling axis (Cheng et al., 2014). Treatment
with IL-37 reduced the expression of HIF-1a, consistent with
previous studies indicating that IL-37 activates AMPK and sup-
presses mTOR (Figure 3G) (Ballak et al., 2014, 2018; Cavalli
and Dinarello, 2018; Cavalli et al., 2017a; Nold et al., 2010).
In TI, metabolites generated by immunometabolic changes
activate chromatin-modifying enzymes, leading to gene-specific
chromatin modifications associated with enhanced transcription
of genes encoding inflammatory cytokines (Netea et al., 2020a).
A key epigenetic mark characterizing TI induced by b-glucan is
the consolidation of histone 3 lysine 4 trimethylation
(H3K4me3) at promoters of genes encoding cytokines (Netea
et al., 2020a). As shown in Figure 3H, monocytes of mice trained
with b-glucan showed an increase of H3Kme4 at the promoters
of TNFa and IL6, which was reduced upon treatment with IL-37.
IL-37 reverses immunometabolic changes
characteristic of TI
Inhibition of glycolysis by IL-37 was paralleled by the reversal of
other metabolic changes characteristic of TI (Arts et al., 2016a).




Figure 2. IL-37 suppresses TI and neutrophil responses
(A) Survival rate of mice to systemic candidiasis following administration of IL-37 and b-glucan. Animal survival was assessed daily for 2 weeks (two experiments,
product limit method of Kaplan and Meier, n = 10 mice per group).
(B–G) In a separate experiment, mice were sacrificed 4 days after C. albicans infection: fungal outgrowth (B); levels of IL-1b (C), IL-6 (D), and TNF-a (E); and levels
of KC (F) and MPO (G) were assessed in the kidneys (two experiments, ANOVA, n = 5 mice per group).
(H) Neutrophil chemotaxis was evaluated using a Bowen chamber assay: migration index: ratio of cells in lower to top chamber (one experiment, ANOVA, n = 4
mice per group).
(I) Histopathologic findings with H&E stain, original magnification 2003; scale bar, 200 mm.
ns, non-significant; *p < 0.05, **p < 0.01, and ***p < 0.005.
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Increased glutamine metabolism through the tricarboxylic acid
(TCA) cycle is a feature of trained monocytes. In this study, in
the absence of isotope tracing analysis, steady-state metabolite
levels indicated an increase in glutamate to fuel the TCA cycle via
transamination to a-ketoglutarate; conversely, glutamate levels
remained unchanged and glutamine accumulated upon IL-37
treatment (Figure 4A). Further effects of TI on the TCA cycle
included accumulation of fumarate and malate. These metabo-
lites stabilize HIF-1a (Arts et al., 2016a; Koivunen et al., 2007;
Tannahill et al., 2013) and promote the epigenetic changes un-
derlying TI (Arts et al., 2016a; Lu et al., 2012). Fumarate and ma-
late were significantly reduced in IL-37-treated mice.
Increased glutamate fuels glutathione synthesis, which is
essential to reduce oxidative stress in activated cells, such as
trained monocytes. Glutathione levels were increased in mono-
cytes from b-glucan-trained mice but were significantly lowered
by treatment with IL-37 (Figure 4A). Increases in cystine, the di-
merized form of rate-limiting precursor cysteine, are consistent
with decreased consumption for glutathione production, as was
observed upon treatment with IL-37 (Figure 4A). Higher reduced
glutathione pools in trained monocytes could also be maintained
by upregulation of the pentose phosphate pathway to generate
NADPH (Figure 3C), which is then used as a cofactor to regen-
erate glutathione pools. Interestingly, monocytes of mice trained
with b-glucan also exhibited increased reactive oxygen species
(ROS) production compared with control, whereas treatment
with IL-37 significantly reduced ROS production (Figure S3).
Purine metabolism is upregulated in TI, mainly as a result of
increased glycolysis (Arts et al., 2016a, 2016b). IL-37 inhibited
purine metabolism and suppressed protein glycosylation pre-
cursors UDP, UDP-glucose, and UDP-GlcNac (Figure 4B). Of
note, these mediators are also required as substrates for mono-
cyte differentiation into macrophages (Jha et al., 2015). Thus,
suppression of UDP, UDP-glucose, and UDP-GlucNac by IL-
37 may alter the natural development of myeloid responses
following infection.
Changes in tryptophan metabolism are observed in TI as well
as other inflammatory states (Arts et al., 2016a, 2016b), as a
result of the activation of IDO1 (Wirthgen and Hoeflich, 2015).
As shown in Figure 4C, tryptophan levels were not significantly
altered by b-glucan or IL-37 treatment; however, tryptophanme-
tabolites 8-methoxykynurenate, ɣ-oxalocrotonate, and nicotin-
amide were significantly increased in trained monocytes,
whereas treatment with IL-37 significantly reduced thesemetab-
olites, thus indicating that IL-37 may suppress tryptophan-asso-
ciated pathways in monocytes (Colabroy and Begley, 2005;
Jung et al., 2009).
DISCUSSION
This study shows that the anti-inflammatory cytokine IL-37 is a
regulator of TI, a pro-inflammatory cell program elicited in mono-
cytes by exposure to pathogens, which is critically involved in
host immune responses. Specifically, IL-37 functions as an in-
hibitor of TI, with relevant consequences on host immunity
against infection.
TI is a pro-inflammatory program of monocytes and macro-
phages, which evolved to provide protection against infections.
Although recognition of several pathogens can induce TI, induc-
tion by theC. albicans cell wall component b-glucan is best char-
acterized (Netea et al., 2020a; Quintin et al., 2012). b-glucan is
recognized by the monocyte receptor Dectin-1, which activates
the AKT/mTOR/HIF-1a signaling axis and induces changes in
cell energy metabolism, such as increased glycolysis and
increased glutaminolysis through the TCA cycle (Arts et al.,
2016a, 2016b; Bekkering et al., 2018; Cheng et al., 2014). Meta-
bolic intermediates generated in these processes modulate the
activity of enzymes involved in remodeling the epigenetic land-
scape of monocytes, leading to key epigenetic changes (i.e.,
H3K4me3) at promoters of genes encoding cytokines at pro-
moters of genes encoding cytokines (Netea et al., 2020a).
Thus, activation of TI programs in monocytes enhances tran-
scription of pro-inflammatory genes, while also providing the en-
ergy that is needed for sustained inflammatory activation. Func-
tionally, this results in hyper-responsiveness to inflammatory
triggers and enhanced cytokine production (Netea et al., 2020a).
In this study, all these mechanisms were prevented by admin-
istration of IL-37. Specifically, effects of IL-37 on monocytes
included suppression of HIF-1a, of glycolysis, of glutaminolysis,
of epigenetic changes (H3K4me3) on genes encoding cytokines,
and of enhanced cytokine production in response to infection,
which are the mechanistic and functional hallmarks of TI. Of
note, functional consequences of reduced cytokine production
bymonocytes also affected recruitment and activation of neutro-
phils, thus resulting in a broad suppression of the host innate im-
mune response.
Figure 3. IL-37 inhibits glycolysis and epigenetic changes of TI
Mice were treated with b-glucan and IL-37 in vivo, and monocytes were obtained from the bone marrow and subjected to metabolic studies.
(A) Partial-least-squares discriminant analysis (PLS-DA) showing differential effects of TI and IL-37 on the metabolic landscape of monocytes.
(B) Pathway analysis showing the main differentially modulated pathways of monocytes during TI or upon concomitant treatment with IL-37.
(C) Changes andmajor modulated precursors in glycolysis and pentose phosphate pathways; y axis indicates relative abundance. In (A)–(C), one experiment, n =
5 mice per group; *p < 0.05, **p < 0.01, and ***p < 0.005; significance not shown whenever not reached.
(D) Analysis of ECARmeasurements on bonemarrow-derivedmonocytes of mice stimulated in vitrowith vehicle (Veh), b-glucan (bglu), or b-glucan in combination
with IL-37 treatment (IL-37/bglu), in basal conditions and after sequential addition of glucose, oligomycin, and 2-DG (representative experiment, n = 3).
(E) Glycolysis and glycolytic capacity ofmonocytes described in (D) (representative experiment, n = 3, unpaired t test; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p <
0.0001).
(F) Gene expression of hexokinase (HK1) and phosphofructokinase (PK) as determined using qPCR in monocytes frommice receiving b-glucan and IL-37 in vivo
(two experiments, n = 3, unpaired t test; *p < 0.05 and **p < 0.01).
(G) Gene expression of HIF1a in monocytes as described in (F) (two experiments, n = 3, unpaired t test; *p < 0.05).
(H) Monocytes were obtained as described in (A)–(C), and chromatin immunoprecipitation (ChIP) against H3K4me3was performed in which enrichment on the IL-
6 or TNF-a promoter was analyzed using qPCR (two experiments, n = 3).




The IL-1 family of cytokines is involved in TI responses
(Moorlag et al., 2018). For example, administration of recombi-
nant IL-1b enhances survival in mice subjected to inoculum of
different pathogens (Czuprynski and Brown, 1987; Pecyk et al.,
1989; van der Meer et al., 1988). In addition, studies of TI
induced by BCG vaccination in humans demonstrated that
enhanced production of IL-1b correlates with the beneficial ef-
fects of vaccination (Arts et al., 2018), whereas in vitro training
of human monocytes is induced by IL-1b itself through epige-
netic reprogramming of cells (Kleinnijenhuis et al., 2014).
IL-37 is a member of the IL-1 family of cytokines that func-
tions as a natural suppressor of innate inflammation (Cavalli
and Dinarello, 2018; Nold et al., 2010) and was thereby a highly
plausible candidate among possible regulators of TI. Of note,
there is no homolog gene for human IL-37 in the mouse, and
it was thus not possible to directly measure IL-37 in response
to TI or to conduct this study using genetically deficient animals
(Cavalli and Dinarello, 2018; Nold et al., 2010); however, exog-
enous administration of human IL-37 to wild-type mice revealed
inhibitory effects on TI. In previous studies from our group, the
anti-inflammatory effects of IL-37 prevented excessive and
detrimental immune responses in septic shock, endotoxemia,
arthritis, and other inflammatory conditions (Ballak et al.,
2014, 2018; Cavalli et al., 2016, 2017a; McNamee et al., 2011;
Nold et al., 2010). Here, we show that IL-37 also inhibits TI,
an appropriate immune mechanism that boosts host immunity
against infection. Thus, the net effects of IL-37 on immunity
are context dependent: suppression of excessive inflammation
is beneficial, whereas suppression of appropriate immune re-
sponses can be detrimental.
IL-37 exerts anti-inflammatory effects through different mech-
anisms of action: intracellular IL-37 translocates to the nucleus,
where it suppresses transcription of pro-inflammatory genes
(Bulau et al., 2014; Li et al., 2019; Ross et al., 2013); extracellular
IL-37 binds the IL-18 receptor a (IL-18Ra) and recruits the IL-1
family receptor 8 (IL-1R8), which also results in suppression of
pro-inflammatory gene expression via inhibition of NF-kB and
MAPK signaling (Li et al., 2015; Nold-Petry et al., 2015). In this
study, we show that signaling through IL-1R8 is needed for inhi-
bition of TI by IL-37.
Figure 4. IL-37 reverses the metabolic changes characteristic of TI
Mice were treated with b-glucan and IL-37 in vivo, and monocytes were obtained from the bone marrow and subjected to metabolic studies.
(A) Changes and major modulated precursors in the TCA cycle.
(B) Changes in protein glycosylation precursors.
(C) Major modulated metabolites in tryptophan metabolism.
The y axis in (A)–(C) indicates relative abundance. One experiment, n = 5 mice per group; *p < 0.05, **p < 0.01, and ***p < 0.005; significance not shown whenever
not reached.




Previous studies from our group showed that during inflamma-
tion, IL-37 restores cell energy metabolism by activating AMPK
and by suppressing mTOR, both key regulator enzymes of
cellular energy homeostasis (Ballak et al., 2014; Cavalli and Di-
narello, 2018; Cavalli et al., 2017a; Nold et al., 2010). Here, we
expand these findings by showing that IL-37 also suppresses
HIF-1a and broadly counteracts the metabolic changes underly-
ing TI. The main metabolic pathways induced by TI and reversed
by treatment with IL-37 included glycolysis, glutaminolysis
through the TCA cycle, purine metabolism, and tryptophan
metabolism. Through this extensive metabolic reprogramming,
IL-37 deprives monocytes of the energy needed to sustain
chronic inflammatory activation, thus suppressing production
of pro-inflammatory cytokines by ‘‘switching off’’ cell metabolic
activation.
In humans, IL-37 primarily functions as a regulatory mecha-
nism to limit excessive inflammation and cytokine production:
accordingly, levels are abnormal in patients with inflammatory
and autoimmune diseases (Cavalli and Dinarello, 2018). The
inhibitory effects of IL-37 on TI observed in this study are fully
consistent with suppression of pro-inflammatory cytokines and
with inhibition of IL-1. The IL37 gene is found as part of the large
IL-1 gene cluster on chromosome 2q12-13, in tight proximity to
the IL-1 genes: when transcription of IL-1 genes is induced by
pro-inflammatory stimuli, IL-37 is simultaneously activated (Cav-
alli and Dinarello, 2018). Many pro-inflammatory stimuli,
including cytokines or engagement of TLRs, are also recognized
inducers of TI: thus, production of IL-37 likely acts as a physio-
logic regulatory mechanism preventing excessive or maladap-
tive activation of TI.
This study has some limitations. Although upregulation of the
cholesterol synthesis pathway is an additional metabolic hall-
mark of TI (Bekkering et al., 2018), no specific lipid extraction
was performed in this study for the assessment of sterol-related
metabolites. Also, although TI is specific tomyeloid cells (i.e., still
inducible in RAG-deficient mice lacking an adaptive immune
system) (Quintin et al., 2012), we cannot formally exclude that
some observed inhibitory effects of IL-37 on TI may depend at
least in part on modulation of adaptive immunity. Strengths of
this study include the relevance of the study question, pertaining
to the regulation of an emerging and pivotal immunemechanism,
and the use of a broad array of relevant methodologies, in order
to capture the intricacy of biological mechanisms underlying
activation of TI. Despite this complexity, our findings point at
one conclusion, that is, IL-37 inhibits TI.
This study has implications for the understanding of human
diseases characterized by excessive activation of TI and hy-
per-responsiveness to inflammatory triggers, ranging from
auto-inflammatory diseases (Cavalli et al., 2019; Kl€uck et al.,
2020) to severe cases of coronavirus disease 2019 (COVID-19)
(Cavalli et al., 2020; Cavalli et al., 2021). Detrimental activation
of TI in these conditions might be quenched by delivery of IL-
37; conversely, targeted inhibition of IL-37 might boost protec-
tive TI responses during infection, vaccination, or cancer (Mulder
et al., 2019; Netea et al., 2020b). Thus, determining the role of in-
hibitors of TI not only has critical implications for the understand-
ing of human disease but also provides a rationale for exploring
novel therapeutic strategies modulating human immunity.
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Koivunen, P., Hirsilä, M., Remes, A.M., Hassinen, I.E., Kivirikko, K.I., and Myl-
lyharju, J. (2007). Inhibition of hypoxia-inducible factor (HIF) hydroxylases by
citric acid cycle intermediates: possible links between cell metabolism and
stabilization of HIF. J. Biol. Chem. 282, 4524–4532.
Li, S., Neff, C.P., Barber, K., Hong, J., Luo, Y., Azam, T., Palmer, B.E., Fujita,
M., Garlanda, C., Mantovani, A., et al. (2015). Extracellular forms of IL-37 inhibit
innate inflammation in vitro and in vivo but require the IL-1 family decoy recep-
tor IL-1R8. Proc. Natl. Acad. Sci. U S A 112, 2497–2502.
Li, S., Amo-Aparicio, J., Neff, C.P., Tengesdal, I.W., Azam, T., Palmer, B.E., Ló-
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
V450 Rat anti-CD11b BD Biosciences Cat# 560455
FITC Rat anti-Mouse Ly-6G BD Biosciences Cat# 551460
H3K4me3 Antibody - ChIP-seq Grade Diagenode Cat# C15410003-50
Bacterial, virus and fungal strains
Candida albicans (Robin) Berkhout (UC820) ATCC ATCC MYA-3573
Chemicals, peptides, and recombinant proteins
Glucan from baker’s yeast (S. cerevisiae) Sigma-Aldrich Cat# G5011-25MG
Lipopolysaccharide (LPS) Sigma-Aldrich Cat# L9641
Recombinant IL-37 isoform b (residues 46–
218)
Prof. Dinarello C.A. N/A
Phosphate Buffered Saline (PBS) Corning Cat# 21-040-CV
RPMI 1640, 1X Corning Cat# 10-040-CV
Penicillin-Streptomycin Solution, 100x Corning Cat# 30-002-CI
SuperScript III First-Strand Synthesis
System
ThermoFisher Scientific Cat# 18080051
Power SYBR Green Master Mi ThermoFisher Scientific Cat# 4368577
Corning Cell-Tak Cell Tissue Adhesive Sigma_Aldrich Cat# DLW354242
Agilent Seahorse XF DMEMMedium pH 7.4 Agilent Cat# 103575-100
Critical commercial assays
Neutrophil Isolation Kit, mouse Miltenyi Biotec Cat# 130-097-658
Mouse CXCL1/KC DuoSet ELISA BioTechne Cat# DY453
Mouse Myeloperoxidase DuoSet ELISA BioTechne Cat# DY3667
Mouse IL-1 beta/IL-1F2 DuoSet ELISA BioTechne Cat# DY401
Mouse IL-6 DuoSet ELISA BioTechne Cat# DY406
Mouse TNF-alpha DuoSet ELISA ouseT
TNFalphaDuoSet ELISA
BioTechne Cat# DY410
L-Lactate Assay Kit (Colorimetric) abcam Cat# ab65331
Cellular ROS Assay Kit (Deep Red) abcam Cat# ab186029
Seahorse XF Glycolysis Stress Test Kit Agilent Cat# 103020-100
MinElute PCR Purification Kit QIAGEN Cat# 28004
Experimental models: Organisms/strains
Male C57BL/6J mice aged 10-12 weeks The Jackson Laboratories Cat# 000664 | B6
Male IL-1R8 deficient (/) kind gift from Dr. Mayumi Fujita. N/A
Oligonucleotides
Forward Primer for Hk1 mRNA:
50-TGCCATGCGGCTCTCTGATG-30
This paper N/A
Reverse Primer for Hk1 mRNA:
50-CTTGACGGAGGCCGTTGGGTT-30
This paper N/A
Forward Primer for Pk mRNA:
50-CCCATCACGGCCCGCAACACT-30
This paper N/A
Reverse Primer for Pk mRNA:
50-ATTCAGCCGAGCCACATTCATTCC-30
This paper N/A
Forward Primer for Hif1a mRNA:
50-CTATGGAGGCCAGAAGAGGGTAT-30
This paper N/A
(Continued on next page)






Further information and requests for resources and reagents should be directed to and will be fulfilled by Prof. Charles Dinarello
(cdinare333@aol.com).
Materials availability
This study did not generate new unique reagents.
Data and code availability
This study did not generate any unique datasets or code.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Male C57BL/6J mice aged 10-12 weeks were purchased from Jackson Laboratories (Bar Harbor, Maine, USA) and housed under
standard conditions. The weight range for all animals used in the experiments was between 21 and 24 g. Male IL-1R8 deficient
(/) mice were a kind gift from Dr. Mayumi Fujita. Animal studies followed the NIH Guidelines for the Care and Use of Laboratory
Animals, as well as protocols approved by the Institutional Animal Care and Use Committees of the University of Colorado Denver,
Aurora, CO, USA and of IRCCS San Raffaele Institute, Milan, Italy.
METHOD DETAILS
Stimuli
The Candida albicans strain ATCC MYA-3573 (UC 820) was used in all experiments. C. albicans was grown overnight in Sabouraud
broth at 37C; cells were harvested by centrifugation, washed twice in sterile PBS and suspended to a concentration of 103 106/mL
prior to inoculum. b-glucan and lipopolysaccharide (LPS) were purchased from Sigma-Aldrich (St. Louis, MO). Sterile PBS (Corning,
Tewksbury, MA) was used as vehicle.
IL-37
IL-37 is transcribed as five different splice variants (IL-37a–e), with IL-37b being the most complete and best-characterized iso-
form (Cavalli and Dinarello, 2018; Dinarello et al., 2016). IL-37b with an N terminus at valine 46 and C terminus at 218 (46-218) was
generated as previously reported (Cavalli et al., 2017a). Briefly, IL-37 residues 46-218 was cloned into a pET21 vector with an
N-terminal 6xHis tag and thrombin cleavage site. Protein was expressed in BL21/DE3 cells at 37C and purified via Ni affinity chro-
matography. Eluted fractions containing IL-37 were dialyzed into 50mM tris, pH 7.2, 100mM NaCl, 1mM EDTA and applied onto an
SP ion exchange using SP fast-flow resin (GE Healthcare). SP ion exchange eluted fractions were concentrated and cleaved with
thrombin to remove the 6xHis tag for a final application to size-exclusion chromatography in PBS using a Superdex-75 (GE
Healthcare).
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Reverse Primer for Hif1a mRNA:
50-CCCACATCAGGTGGCTCATAA-30
This paper N/A
Forward Primer for Il6 mRNA:
50-TGCACAAAATTTGGAGGTGA-30
This paper N/A
Reverse Primer for Il6 mRNA:
50-ACCCAACCTGGACAACAGAC-30
This paper N/A
Forward Primer for Tnfa mRNA:
50-CTTGGGCCAGTGAGTGAAAG-30,
This paper N/A




BD FACS Diva software BD Biosciences N/A
MetaboAnalyst package Xia and Wishart, 2016 https://www.metaboanalyst.ca
GraphPad Prism GraphPad Software Inc https://www.graphpad.com
GENE E software Broad Institute N/A





To induce trained immunity in vivo in mice, a single dose of b-glucan 1 mg in 200 mL PBS was administered intraperitoneally 3 days
before infection (day 3), as previously reported (Mitroulis et al., 2018). Recombinant human IL-37 1mg/mouse in 200 mL PBS was
administered intraperitoneally on day 3 (2 h prior to administration of b-glucan), day 2, and day 1. On day 0, mice were injected
intravenously with C. albicans yeast (23 106 CFU/mouse suspended in 100 mL PBS). Survival and changes in body weight were as-
sessed daily for 2 weeks. In a separate experiment, animals were sacrificed on day 4 after infection to assess the tissue fungal
burden: kidneys were aseptically removed, weighted, and homogenized in sterile PBS using a tissue grinder. The number of
C. albicans cells in the tissues was then determined by plating serial dilutions on Sabouraud dextrose agar plates. The number of
CFU was assessed after 24 h of incubation at 37C, and expressed as log CFU/g tissue.
Histopathology
Kidneys were harvested for histological examination at day 4 after infection. The tissues were fixed in formalin and embedded in
paraffin. Tissue sections (5 mm) were stained with Hematoxylin & Eosin (H&E) to study cell influx. Pictures were obtained from histol-
ogy slides using a Zeiss microscope fitted with an Axiocam camera.
Sample processing and cell isolation
Micewere anesthetized andwhole bloodwas obtained by orbital bleeding into heparinized tubes prior to sacrifice. Bonemarrow cells
were collected from both femurs through flushing with ice-cold RPMI, passed through a 70-mmcell strainer, washed, and suspended
in RPMI (Corning) supplemented with 1%penicillin/streptomycin at 5x106 cell/ml. Cells were seeded at 0.5x106/well in 96-flat bottom
well plates in 200 ml RPMI, and incubated for 2 h at 37C in 5% CO2; adherent monocytes were isolated by removing non-adherent
cells with warm RPMI.
Neutrophil chemotaxis assays
Neutrophils were isolated from the bone marrow of healthy, unchallengedmice using the Neutrophil isolation kit (Miltenyi), incubated
with fluorescently labeled antibodies against mouse CD11b V450, and Ly6g FITC (BD Bioscience) or corresponding isotype controls,
and fixed with 2% paraformaldehyde. Neutrophil sorting and assessment of purity (> 95%) and count were performed by flow cy-
tometry using BD FACSCanto II (BD Biosciences). Data was analyzed using BD FACS Diva software (BD Biosciences). Neutrophil
chemotaxis was evaluated with a migration (or ‘Boyden chamber’) assay: the kidney homogenate solution was placed into the lower
chamber, while cells (1 3 106) were placed into the upper chamber, separated by a transwell 5.0 mm pore permeable membrane
(Corning). After incubation for 3 h at 37C and 5% CO2, counting cells in both chambers allowed quantification of migration, ex-
pressed as ‘migration index’ (ratio of cells in the lower to top chamber).
Determination of soluble factors
Levels of mouse KC, MPO, IL-1b, IL-6, and TNFa in kidney homogenates were determined with appropriate ELISA kits (BioTechne,
Minneapolis, MN). Lactate was measured with a Colorimetric Assay Kit (Abcam, Cambridge, MA).
ROS production assay
b-glucan and IL-37 were administered in vivo and monocytes were collected as described above and seeded overnight in a 96-well
plate at a concentration of 2.5 3 104 cells per well. ROS production was determined using a Cellular ROS Assay Kit per manufac-
turer’s recommendations (Abcam, Cambridge, MA). Relative ROS quantitation was determined as percent of change from control
after background subtraction.
Gene expression
b-glucan and IL-37 were administered in vivo and monocyte collection were performed as described above. RNA was then isolated
using Trizol (Thermo Fisher Scientific) and synthesized in cDNA using SuperScript III First-Strand (Thermo Fisher Scientific). Quan-
titative PCR (qPCR) was performed on cDNA using Power SYBR Green PCR master mix (Thermo Fisher Scientific) on Biorad CFX96
Real time system. Gene expression was assessed for the following mRNAs: Hk1 (forward 50TGCCATGCGGCTCTCTGATG-30 and
reverse, 50- CTTGACGGAGGCCGTTGGGTT-30), Pk (forward 50 - CCCATCACGGCCCGCAACACT 30 and reverse50ATTCAGC
CGAGCCACATTCATTCC-30) and Hif1a (forward 50-CTATGGAGGCCAGAAGAGGGTAT-30 50-CCCACATCAGGTGGCTCATAA-30)
with gapdh used as a reference gene.
Metabolic studies
Monocytes frommice treated with b-glucan and IL-37 in vivowere lysed in 100 ml of ice-cold extraction buffer (methanol: acetonitrile:
water 5:3:2), vortexed for 30 min at 4C, and centrifuged at 15000 g for 10 minutes at 4C. After discarding protein pellets, 20 ml of the
supernatant fractions were assayed as previously described with additional adjustments (Nemkov et al., 2017). Briefly, the analytical
platform employs a Vanquish UHPLC system (Thermo Fisher Scientific, San Jose, CA, USA) coupled online to a Q Exactive mass
spectrometer (Thermo Fisher Scientific, San Jose, CA, USA). Samples were resolved over a Kinetex C18 column, 2.1 3 150 mm,
1.7 mm particle size (Phenomenex, Torrance, CA, USA) equipped with a guard column (SecurityGuardTM Ultracartridge – UHPLC




C18 for 2.1 mm ID Columns – AJO-8782 – Phenomenex, Torrance, CA, USA) using an aqueous phase (A) of water and 0.1% formic
acid and a mobile phase (B) of acetonitrile and 0.1% formic acid for positive ion polarity mode, and an aqueous phase (A) of water:
acetonitrile (95:5) with 1 mM ammonium acetate and amobile phase (B) of acetonitrile:water (95:5) with 1 mM ammonium acetate for
negative ion polarity mode. Samples were eluted from the column using either an isocratic elution of 5% B flowed at 250 ml/min and
25C or a gradient from 5% to 95% B over 1 minute, followed by an isocratic hold at 95% B for 2 minutes, flowed at 400 ml/min and
30C. The Q Exactive mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA) was operated independently in positive or
negative ion mode, scanning in Full MS mode (2 mscans) from 60 to 900 m/z at 70,000 resolution, with 4 kV spray voltage, 15 shealth
gas, 5 auxiliary gas. Calibration was performed prior to analysis using the PierceTM Positive and Negative Ion Calibration Solutions
(Thermo Fisher Scientific). Acquired data was then converted from .raw to .mzXML file format using Mass Matrix (Cleveland, OH,
USA). Metabolite assignments, isotopologue distributions, and correction for expected natural abundances of deuterium, 13C,
and 15N isotopes were performed using MAVEN (Princeton, NJ, USA) (Clasquin et al., 2012). Graphs, heatmaps and statistical an-
alyses (either T-Test or ANOVA), metabolic pathway analysis, PLS-DA and hierarchical clustering was performed using the Metab-
oAnalyst package (https://www.metaboanalyst.ca) (Xia and Wishart, 2016).
Extracellular Flux Analyzer (Seahorse)
Bone marrow-derived monocytes were treated with IL-37 (10ng/ml) for 2 hours prior to stimulation with b-glucan (200ng/mL) or
vehicle for 12 hours. Five days later, OCR and ECARweremeasured by Seahorse XFe96 Analyzer (Agilent Technologies, Santa Clara,
CA, USA) using SeaHorse XF96 Glycolysis Stress Test, following the manufacturer’s instructions. Briefly, the day of the assay cells
were counted and attached to 96-well Seahorse cell culture microplates, pre-coated with Corning Cell-Tak (Life Sciences) according
to manufacturer’s instructions, at a density of 70,000 cells per well, in Seahorse XF Base Medium pH 7.4 with 1 mM HEPES (Agilent
Technologies). The medium was supplemented with 2 mM L-glutamine for Glycolysis Stress Test assay. The plate was incubated at
37 C for 1 h in a non-CO2 incubator. OCR was assessed at baseline. For the Glycolysis Stress Test assay after ECAR baseline mea-
surements, glucose, oligomycin A, and 2-deoxy-glucose (2-DG) were added sequentially to each well to reach the final concentra-
tions of 10mM, 2 mM, and 50mM, respectively. Glycolysis was calculated by subtracting the last ECARmeasurement before glucose
injection from the maximum ECAR measurement before oligomycin injection; the glycolytic capacity was calculated by subtracting
the last ECAR measurement before glucose injection from the maximum ECAR measurement before 2-DG injection. OCR data are
expressed as pmol of oxygen per minute per arbitrary units (pmol/min), ECAR data as mpH per minute per arbitrary units (mpH/min).
Chromatin Immunoprecipitation
Purified cells were fixed with 1% formaldehyde (Sigma) at a concentration of approximately 106 cells/mL. Fixed cell preparations
were sonicated using a Diagenode Bioruptor UCD-300 for 3 3 10 min (30 s on; 30 s off). 33 mL of chromatin (one million cells)
were incubated with 255 mL dilution buffer, 12 mL protease inhibitor cocktail and 0.51 mL of H3K4me3 antibody (Diagenode) and
incubated overnight at 4C with rotation. Protein A/G magnetic beads were washed in dilution buffer with 0.15% SDS and 0.1%
BSA, added to the chromatin/antibody mix and rotated for 60 min at 4C. Beads were washed with 500 mL buffer for 5 min at 4C
with five rounds of washes. After washing chromatin was eluted using elution buffer for 20 min. Supernatant was collected, 8 mL
5M NaCl, 2 mL proteinase K were added and samples were incubated for 4 h at 65C. Finally, samples were purified using
QIAGEN; QiaquickMinElute PCR purification Kit and eluted in 20mL EB. Primer pairs employed for quantitative PCRwere as follows:
Il6 forward: TGCACAAAATTTGGAGGTGA; Il6 reverse: ACCCAACCTGGACAACAGAC. Tnfa forward: CTTGGGCCAGTGAGT-
GAAAG; Tnfa reverse: TAGCCAGGAGGGAGAACAGA.
QUANTIFICATION AND STATISTICAL ANALYSIS
Significance of differences was evaluated with Mann-Whitney or ANOVA test using GraphPad Prism (GraphPad Software Inc, La
Jolla, CA). Differences in survival experiments were calculated using the product limit method of Kaplan andMeier. Hierarchical clus-
tering analysis for metabolic studies was performed with GENE E software (Broad Institute). Detailed information on each experiment
is provided in the respective Figure Legends. Statistical significance was set at p < 0.05.
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